Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., . . . Pedersen, T. R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial. The lancet. Diabetes & endocrinology, 5(12), 941. https://doi.org/10.1016/S2213-8587(17)30313-3
Citace podle Chicago (17th ed.)Sabatine, Marc S., et al. "Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and Without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial." The Lancet. Diabetes & Endocrinology 5, no. 12 (2017): 941. https://doi.org/10.1016/S2213-8587(17)30313-3.
Citace podle MLA (9th ed.)Sabatine, Marc S., et al. "Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and Without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial." The Lancet. Diabetes & Endocrinology, vol. 5, no. 12, 2017, p. 941, https://doi.org/10.1016/S2213-8587(17)30313-3.